166 related articles for article (PubMed ID: 34323266)
21. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
Hideshima T; Bradner JE; Wong J; Chauhan D; Richardson P; Schreiber SL; Anderson KC
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8567-72. PubMed ID: 15937109
[TBL] [Abstract][Full Text] [Related]
22. The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.
Negmeldin AT; Knoff JR; Pflum MKH
Eur J Med Chem; 2018 Jan; 143():1790-1806. PubMed ID: 29150330
[TBL] [Abstract][Full Text] [Related]
23. Activation of histone deacetylase-6 induces contractile dysfunction through derailment of α-tubulin proteostasis in experimental and human atrial fibrillation.
Zhang D; Wu CT; Qi X; Meijering RA; Hoogstra-Berends F; Tadevosyan A; Cubukcuoglu Deniz G; Durdu S; Akar AR; Sibon OC; Nattel S; Henning RH; Brundel BJ
Circulation; 2014 Jan; 129(3):346-58. PubMed ID: 24146251
[TBL] [Abstract][Full Text] [Related]
24. Recent advances in the discovery of potent and selective HDAC6 inhibitors.
Wang XX; Wan RZ; Liu ZP
Eur J Med Chem; 2018 Jan; 143():1406-1418. PubMed ID: 29133060
[TBL] [Abstract][Full Text] [Related]
25. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo.
Zhu QY; Wang Z; Ji C; Cheng L; Yang YL; Ren J; Jin YH; Wang QJ; Gu XJ; Bi ZG; Hu G; Yang Y
Cell Death Dis; 2011 Jan; 2(1):e117. PubMed ID: 21368888
[TBL] [Abstract][Full Text] [Related]
26. Overexpressed HDAC8 in cervical cancer cells shows functional redundancy of tubulin deacetylation with HDAC6.
Vanaja GR; Ramulu HG; Kalle AM
Cell Commun Signal; 2018 May; 16(1):20. PubMed ID: 29716651
[TBL] [Abstract][Full Text] [Related]
27. Selective HDAC6 inhibition prevents TNF-α-induced lung endothelial cell barrier disruption and endotoxin-induced pulmonary edema.
Yu J; Ma Z; Shetty S; Ma M; Fu J
Am J Physiol Lung Cell Mol Physiol; 2016 Jul; 311(1):L39-47. PubMed ID: 27190059
[TBL] [Abstract][Full Text] [Related]
28. Structural insights into HDAC6 tubulin deacetylation and its selective inhibition.
Miyake Y; Keusch JJ; Wang L; Saito M; Hess D; Wang X; Melancon BJ; Helquist P; Gut H; Matthias P
Nat Chem Biol; 2016 Sep; 12(9):748-54. PubMed ID: 27454931
[TBL] [Abstract][Full Text] [Related]
29. HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases.
Li G; Jiang H; Chang M; Xie H; Hu L
J Neurol Sci; 2011 May; 304(1-2):1-8. PubMed ID: 21377170
[TBL] [Abstract][Full Text] [Related]
30. Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].
Lee JH; Yao Y; Mahendran A; Ngo L; Venta-Perez G; Choy ML; Breslow R; Marks PA
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12005-10. PubMed ID: 26371309
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.
Namdar M; Perez G; Ngo L; Marks PA
Proc Natl Acad Sci U S A; 2010 Nov; 107(46):20003-8. PubMed ID: 21037108
[TBL] [Abstract][Full Text] [Related]
32. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
[TBL] [Abstract][Full Text] [Related]
34. How to Distinguish Between the Activity of HDAC1-3 and HDAC6 with Western Blot.
Beyer M; Kiweler N; Mahboobi S; Krämer OH
Methods Mol Biol; 2017; 1510():355-364. PubMed ID: 27761834
[TBL] [Abstract][Full Text] [Related]
35. Histone deacetylase 6 interacts with the microtubule-associated protein tau.
Ding H; Dolan PJ; Johnson GV
J Neurochem; 2008 Sep; 106(5):2119-30. PubMed ID: 18636984
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
37. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes.
Choi SY; Ryu Y; Kee HJ; Cho SN; Kim GR; Cho JY; Kim HS; Kim IK; Jeong MH
Vascul Pharmacol; 2015 Sep; 72():130-40. PubMed ID: 25921924
[TBL] [Abstract][Full Text] [Related]
38. PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia.
Gawel JM; Shouksmith AE; Raouf YS; Nawar N; Toutah K; Bukhari S; Manaswiyoungkul P; Olaoye OO; Israelian J; Radu TB; Cabral AD; Sina D; Sedighi A; de Araujo ED; Gunning PT
Eur J Med Chem; 2020 Sep; 201():112411. PubMed ID: 32615502
[TBL] [Abstract][Full Text] [Related]
39. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma.
Vogl DT; Raje N; Jagannath S; Richardson P; Hari P; Orlowski R; Supko JG; Tamang D; Yang M; Jones SS; Wheeler C; Markelewicz RJ; Lonial S
Clin Cancer Res; 2017 Jul; 23(13):3307-3315. PubMed ID: 28053023
[No Abstract] [Full Text] [Related]
40. Modulation of histone deacetylase 6 (HDAC6) nuclear import and tubulin deacetylase activity through acetylation.
Liu Y; Peng L; Seto E; Huang S; Qiu Y
J Biol Chem; 2012 Aug; 287(34):29168-74. PubMed ID: 22778253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
